What is William Blair’s Estimate for TPST FY2024 Earnings?

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Equities researchers at William Blair dropped their FY2024 earnings per share estimates for shares of Tempest Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of ($1.45) for the year, down from their previous estimate of ($1.42). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Tempest Therapeutics’ Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($2.12) EPS and FY2027 earnings at ($2.26) EPS.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04).

TPST has been the subject of a number of other reports. Piper Sandler decreased their target price on Tempest Therapeutics from $8.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $47.00 price objective on shares of Tempest Therapeutics in a research report on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $20.00.

Tempest Therapeutics Stock Performance

Shares of NASDAQ TPST opened at $0.89 on Monday. Tempest Therapeutics has a 52-week low of $0.83 and a 52-week high of $6.00. The stock has a market cap of $22.43 million, a P/E ratio of -0.58 and a beta of -1.78. The firm has a 50 day moving average price of $1.19 and a 200 day moving average price of $1.92.

Institutional Trading of Tempest Therapeutics

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in Tempest Therapeutics in the third quarter valued at approximately $34,000. Dimensional Fund Advisors LP bought a new position in Tempest Therapeutics during the 2nd quarter worth $55,000. Virtu Financial LLC raised its stake in Tempest Therapeutics by 69.2% in the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock worth $112,000 after purchasing an additional 11,689 shares in the last quarter. Empower Advisory Group LLC acquired a new stake in shares of Tempest Therapeutics in the third quarter valued at approximately $49,000. Finally, Fullcircle Wealth LLC acquired a new position in Tempest Therapeutics in the 3rd quarter valued at $87,000. Institutional investors and hedge funds own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.